

Reduction of Pain-Causing Inflammation in Post-Operative Lumbar Patients In a Clinical Trial, Provant® Therapy was Associated with a Decrease in hsCRP, Indicating a Reduction in Pain-Causing Inflammation




- C-reactive protein (CRP) is a protein that increases in the blood with inflammation and infection, as well as following a heart attack, surgery, or trauma. The high-sensitivity CRP (hsCRP) test measures low levels of CRP in the blood to identify inflammation.¹
- Subjects completed a multicenter, randomized, sham-controlled trial. Treatments were twice a day for 60 days.
- 3 trial arms: Current Provant Therapy 42µs pulse, experimental 38µs pulse, and inactive sham.
- hsCRP levels were assayed as a biomarker of inflammation at trial enrollment (baseline) and at the end of the trial.
- A decrease in the mean hsCRP level in the Provant Therapy 42µs group suggests that Provant is having a therapeutic effect on inflammation, compared to experimental 38µs and sham arms which had mean increases in hsCRP.
- Provant Therapy resulted in an hsCRP reduction at 3 weeks, and the reduction was sustained over the 60 day period compared to sham.
- Energetics matter: Different energetic settings have a dramatic effect on clinical efficacy.²


The reduction of the inflammatory marker hsCRP was consistent with a beneficial effect of Provant Therapy over sham control, and over an experimental energetic setting, in pain reduction

Results

hsCRP: Active Provant Therapy Achieved a Reduction in hsCRP, whereas Experimental and Sham increased (mg/L)



Back Pain: Active Provant Therapy Achieved Clinically Meaningful Pain Reduction, whereas Experimental and Sham did not (11-point scale)



SUMMARY

hsCRP Reduction Using Provant Therapy

- Multicenter, randomized, sham-controlled trial assessing pain reduction with Provant Therapy treatment.
- C-reactive protein (CRP) is a protein that increases in the blood with inflammation. Inflammation is often a cause of pain.
- Provant Therapy resulted in an improvement in hsCRP vs. experimental and sham control arms, indicating a therapeutic effect on inflammation.

Sources

1. American Association for Clinical Chemistry. <https://labtestsonline.org/tests/high-sensitivity-c-reactive-protein-hs-crp>
2. Sorrell, R.G. Evaluation of pulsed electromagnetic field therapy for the treatment of chronic postoperative pain following lumbar surgery: a pilot, double-blind, randomized, sham-controlled clinical trial. *Journal of Pain Research*, 2018:11, 1209-1222.

The Provant Therapy System is indicated for adjunctive use in the palliative treatment of postoperative pain and edema of soft tissue. Provant received FDA clearance in 1997, 2010, and 2013. Prior to use, please see the Provant Instruction Manual for more information on indications, contraindications, precautions, warnings and operator's instructions. Regenesi, Provant, Energy Starburst logo, and the color yellow as applied to the Provant Therapy System are registered trademarks of Regenesi Biomedical, Inc., Scottsdale AZ.

Provant[®]
Therapy System



Regenesi Biomedical, Inc.

5301 N. Pima Road
Scottsdale, AZ 85250
Toll Free: (877) 970.4970
Fax: (866) 857.8792
www.regenesibio.com


REGENESIS[®]
BIOMEDICAL